Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)

Cerci, Juliano Júlio; Fanti, Stefano; Lobato, Enrique Estrada; Kunikowska, Jolanta; Alonso, Ómar; Medina, Sevastian; Novruzov, Fuad; Lengana, Thabo; Granados, Carlos; Kumar, Rakesh; Rangarajan, Venkatesh; Al‐Ibraheem, Akram; Hourani, Mukbil; Ali, Nor Salita; Ahmad, Azra; Keidar, Zohar; Küçük, Özlem; Elboğa, Umut; Bogoni, Mateos; Páez, Diana

doi:10.2967/jnumed.120.261886

Cited by 35 publications

(34 citation statements)

References 45 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our survey is in line with this finding and shows that most of the participants would use PSMA PET imaging in the setting of biochemical recurrence and at a PSA level between 0.2 and 0.5 ng/ mL. In several studies, the probability of positive PSMA PET/CT at biochemical recurrence has been clearly demonstrated to increase with higher PSA values and a shorter PSA doubling time [17][18][19]. Of note, PSMA PET/CT seems to be equally useful in the diagnostic workup and treatment planning in patients with PSA recurrence after curative-intent EBRT [20,21].…”

Section: Discussionsupporting

confidence: 84%

The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey

Borkowetz¹,

Linxweiler²,

Fussek³

et al. 2022

Urol Int

View full text Add to dashboard Cite

Introduction: Prostate-specific membrane antigen (PSMA)-based imaging and theranostics have played an important role in the diagnosis, staging, and treatment of prostate cancer (PCa). We aimed to evaluate the acceptance and use of PSMA theranostics among German urologists. Methods: An anonymous online questionnaire was sent via survio.com to the members of the German Society of Urology (DGU). Results: Seventy-two percent of participants performed PSMA positron emission tomography (PET) imaging regularly in biochemically recurrent PCa. Overall, 61% of participants considered PSMA-radioligand therapy to be very useful or extremely useful. PSMA PET imaging in high-risk PCa is more often considered by urologists working in a university setting than in nonuniversity settings or medical practices (51% vs. 25%, p < 0.001). Most perform PSMA-radioligand therapy as an option after all approved systemic treatments for metastatic castration-resistant PCa (56%) or after cabazitaxel (14%). A total of 93.9% and 70.3% of respondents consider the lack of reimbursement by health insurance to be the main obstacle to using PSMA PET imaging or radioligand therapy, respectively. Discussion/Conclusion: PSMA-based imaging/theranostics are already widely applied but would find even more widespread use if reimbursement is clearly regulated by health insurance in Germany.

show abstract

Section: Discussionsupporting

confidence: 84%

The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey

Borkowetz¹,

Linxweiler²,

Fussek³

et al. 2022

Urol Int

View full text Add to dashboard Cite

show abstract

“…The use of ADT was not found to be associated with PSMA PET positivity, while some previous literature has shown a significant increase in the rates of positive PSMA PET in patients undergoing ADT 36 . In this study, 17/21 (80.9%) of patients who were on ADT had a positive PSMA PET/CT, while only 17/31 (54.8%) of patients who did not receive ADT had a positive PSMA PET/CT.…”

Section: Discussioncontrasting

confidence: 62%

68Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy

Haidar

Abi‐Ghanem

Moukaddam

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Biochemical recurrence (BCR) of prostate cancer (PCa) occurs in about 25% of patients treated with radical prostatectomy (RP) and up to 45% in patients who receive external beam radiotherapy (RT). Early diagnosis of PCa recurrence is of high importance for successful salvage therapy. The aim of the present study is to analyze the efficacy of 68 Ga-PSMA PET/CT in detecting the presence of local and/or systemic disease in patients with a history of PCa who have BCR. A total of 52 PCa patients with BCR referred for 68 Ga-PSMA PET/CT were recruited from the American University of Beirut Medical Center between November 2017 and December 2019. We compared the performance of PSMA PET/CT to the results and clinical factors based on follow up: PSA, PSA kinetics, primary treatment, and Gleason score. The relationship between the PET/CT findings and clinical indicators of disease were assessed by univariate and multivariate logistic regression. From a total of 52 patients, 34 (65.4%) had positive PSMA-PET/CT scans. Among those, 8/34 (23.5%) received primary RT. For all patients with a positive PSMA-PET: the detection rate was 2/4 (50%) for PSA < 0.2, 5/10 (50%) for PSA 0.2–0.49, 3/6 (50%) for PSA 0.5–0.99, 6/12 (50%) for PSA 1–1.99, 8/9 (88.9%) for PSA 2–3.99, and 10/11 (90.9%) for PSA 4–10.PSMA-PET/CT positivity was significantly associated with PSA level at time of PET scan, PSA doubling time, Gleason score and TNM staging. However, it did not show a significant correlation with radiotherapy as primary treatment, ongoing androgen deprivation therapy (ADT), time to relapse, and initial PSA before therapy. In our single center prospective trial, 68 Ga-PSMA PET/CT successfully detected the recurrence of PCa in patients with BCR. Scan positivity was significantly associated with PSA level at time of PET scan, PSA doubling time, Gleason score, and TNM staging. PSMA- PET/CT is a highly promising modality in the work up of patients with PCa in the setting of BCR for earlier detection of disease recurrence.

show abstract

“…As a matter of fact, this study is by far the largest prospective trial to be conducted, evaluating 1004 patients from 4 different continents (Africa, America, Asia, and Europe). Despite being a relatively novel modality, this study proves the reliability as well as feasibility of 68Ga PSMA PET/CT in achieving similar accuracy results among all the four continents while helping other physicians seek the best treatment options possible [22] .…”

Section: Participation In Multicentric Prospective Trialsmentioning

confidence: 61%

“…In a field where prospective trails play a vital role in determining the capability of theranostic impact on both detection and management, Arab World representatives from both Jordan and Lebanon participated in a large-scale prospective trail to assess the impact of 68 Ga PSMA PET/CT in the detection of early relapsed prostate cancer after radical therapy [22] . As a matter of fact, this study is by far the largest prospective trial to be conducted, evaluating 1004 patients from 4 different continents (Africa, America, Asia, and Europe).…”

Section: Participation In Multicentric Prospective Trialsmentioning

confidence: 99%

Theranostics in the Arab World; Achievements & Challenges

Al‐Ibraheem¹,

Abdlkadir²

2022

JMJ

Self Cite

View full text Add to dashboard Cite

In nuclear medicine, theranostics (combining therapy and diagnostics in one platform) is made possible through the utilization of radiopharmaceuticals for both therapeutic and diagnostic purposes by targeting one specific tumor receptor or certain molecular pathway.To make radiopharmaceuticals biologically relevant compounds, receptor ligands must be labeled with radionuclides. The possible applications are multifold and include: in vivo visualization of tumor biology; diagnosis and tumor staging; therapy planning and treatment of specific tumors.The application of theranostics results in giving the right treatment to the right patient at the right time, which is expected to improve therapeutic efficacy and increase overall compliance to therapy. For example, theranostics can be used to determine the heterogeneity of cancer lesions, which is one of the most difficult aspects of therapeutic success, allow the identification of patients who will benefit from therapy, avoid unnecessary conventional therapies, and implement salvage treatments for those who need them.The use of theranostics has seen unprecedented value for cancer patients in the last decade. Several radiopharmaceuticals are currently in use in clinical practice (e.g., [68Ga/177Lu] DOTATATE), while dozens more are still in the preclinical stages.The goal of this review article is to cover the current and future status of nuclear theranostics, particularly in the Arab world, with a focus on expanding the discipline beyond neuroendocrine tumors, castration-resistant prostate cancers, and differentiated thyroid cancers. Furthermore, representatives from different Arab countries were invited to describe their recent understanding and contributions to drive innovation in this evolving field.

show abstract

Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)

Abstract: Diagnostic performance and clinical impact of 68 Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).

Cited by 35 publications

References 45 publications

The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey

The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey

68Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy

Theranostics in the Arab World; Achievements & Challenges

Contact Info

Product

Resources

About